Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719592 | 0.95 | MET (0.54) | RAB9AEGLN1METALDH1A1CD274 | |
| SCHEMBL4715686 | 0.89 | HPGD (0.52) | RAB9AEGLN1METALDH1A1NPSR1 | |
| SCHEMBL5615645 | 0.86 | RAB9A (0.59) | RAB9AEGLN1METALDH1A1LMNA | |
| SCHEMBL5616134 | 0.85 | KDM1A (0.51) | RAB9AEGLN1SMN1; SMN2 | |
| SCHEMBL4718388 | 0.84 | RAB9A (0.52) | RAB9AEGLN1ALDH1A1LMNAKMT2A | |
| SCHEMBL4717221 | 0.82 | RAB9A (0.59) | RAB9AEGLN1ALDH1A1LMNA | |
| SCHEMBL5615905 | 0.82 | RAB9A (0.58) | RAB9AEGLN1ALDH1A1 | |
| SCHEMBL8358827 | 0.82 | RAB9A (0.61) | RAB9AEGLN1ALDH1A1MEN1KMT2A | |
| SCHEMBL5615861 | 0.81 | RAB9A (0.58) | RAB9AEGLN1ALDH1A1KDM4E | |
| SCHEMBL5615595 | 0.81 | CYP2C9 (0.56) | RAB9ATSHRALDH1A1LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560815-B1 | NOVEL PYRIMIDINE-4,6-DICARBOXAMIDES FOR THE SELECTIVE INHIBITION OF COLLAGENASES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-03-12 | — | — | EP | claimed |
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | claimed |
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | US | claimed |
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | MMP13, DPYD, MMP1 | RAB9A 3108/4885EGLN1 1003/4885TSHR 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.